아르보바이러스 검사 시장 분석 및 예측 : 유형, 제품 유형, 서비스, 기술, 용도, 프로세스, 최종 사용자, 방법, 단계(-2035년)

The global Arbovirus Testing Market is projected to grow from $9.2 billion in 2025 to $18.9 billion by 2035, at a compound annual growth rate (CAGR) of 7.5%. Arbovirus testing is driven by large-scale disease transmission and outbreak surveillance across dengue, Zika, chikungunya, and West Nile viruses. Each year, 390+ million dengue infections occur globally, with about 100-120 million symptomatic cases requiring laboratory confirmation. Chikungunya outbreaks have affected populations across 119 countries covering ~5.6 billion people at risk, while dengue alone is endemic in more than 100 countries. Annual reported dengue cases have risen from ~505,000 (2000) to over 5.2 million (2019), reflecting rapidly expanding testing demand. In outbreak years, individual countries can record hundreds of thousands to millions of suspected cases, each requiring ELISA or RT-PCR confirmation.

The type segment of the arbovirus testing market includes dengue, Zika virus, chikungunya, yellow fever, West Nile virus, Japanese encephalitis, and others. Among these, dengue testing is the leading subsegment, driven by the high global disease burden, frequent outbreaks in tropical and subtropical regions, and strong demand for early and accurate diagnostic solutions. Chikungunya and Zika virus testing also hold significant shares due to recurring epidemics and increasing surveillance programs. Meanwhile, West Nile virus and Japanese encephalitis testing represent the fastest-growing segments, supported by expanding vector-borne disease monitoring initiatives and rising public health awareness across endemic and emerging regions globally.

The end user segment of the arbovirus testing market includes hospitals, diagnostic laboratories, research institutes, public health organizations, and others. Among these, diagnostic laboratories are the leading subsegment, driven by high testing volumes, advanced diagnostic infrastructure, and increasing demand for accurate and rapid molecular and serological testing. Hospitals also account for a significant share due to their role in patient diagnosis and emergency care during outbreaks. Meanwhile, public health organizations represent the fastest-growing segment, supported by rising government-led surveillance programs, epidemic preparedness initiatives, and large-scale disease monitoring efforts. Research institutes continue to contribute steadily through ongoing studies and vaccine development activities.

Geographical Overview

North America is the leading region in the Arbovirus Testing Market due to its strong public health surveillance systems, advanced diagnostic infrastructure, and high awareness of vector-borne diseases such as dengue, Zika, West Nile, and chikungunya. The United States dominates the region, supported by robust laboratory networks, rapid adoption of molecular diagnostics like RT-PCR, and widespread use of ELISA-based testing kits. Continuous government funding for infectious disease monitoring and strong presence of leading diagnostic companies further strengthen market growth. Increasing climate variability and travel-related disease transmission also drive testing demand, reinforcing North America's leadership in arbovirus diagnostics globally.

Asia-Pacific is the fastest-growing region in the Arbovirus Testing Market due to high prevalence of mosquito-borne diseases, expanding population density, and improving healthcare infrastructure. Countries such as India, China, Indonesia, Thailand, and the Philippines frequently face outbreaks of dengue, chikungunya, and Japanese encephalitis, significantly increasing diagnostic demand. Rising government initiatives for early disease detection, vector control programs, and expanding laboratory networks are boosting adoption of rapid diagnostic kits and molecular testing methods. Growing awareness among healthcare providers and patients, along with increasing investments in public health systems, is accelerating market growth, making Asia-Pacific the highest-growth region globally.

Key Trends and Drivers

Rising Incidence of Arboviral Outbreaks Globally:

A key driver of the arbovirus testing market is the increasing frequency and geographic spread of arboviral diseases due to climate change, urbanization, and global travel. Diseases such as dengue, Zika, chikungunya, and West Nile virus are expanding into new regions, increasing the global disease burden. Rising mosquito populations and changing environmental conditions are contributing to more frequent outbreaks, particularly in tropical and subtropical regions. This growing incidence is creating strong demand for early and accurate diagnostic tools to support timely treatment and containment. Public health authorities are increasingly investing in surveillance and testing infrastructure to manage outbreak risks effectively.

Shift Toward Multiplex and Syndromic Diagnostic Panels:

A key trend in the arbovirus testing market is the growing adoption of multiplex and syndromic diagnostic panels that can simultaneously detect multiple arboviruses such as dengue, Zika, chikungunya, and West Nile virus. This approach is particularly valuable in regions where symptoms overlap and clinical differentiation is difficult. Laboratories and point-of-care settings are increasingly using PCR-based multiplex assays and rapid immunoassay panels to improve diagnostic speed and accuracy. This trend is driven by the need for faster outbreak identification and efficient disease surveillance. It is significantly improving clinical decision-making and enabling more effective public health response strategies globally.

Research Scope

• Estimates and forecasts the overall market size across type, application, and region.
• Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
• Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
• Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
• Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
• Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
• Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

• 1.1 Market Size and Forecast
• 1.2 Market Overview
• 1.3 Market Snapshot
• 1.4 Regional Snapshot
• 1.5 Strategic Recommendations
• 1.6 Analyst Notes

2 Market Highlights

• 2.1 Key Market Highlights by Type
• 2.2 Key Market Highlights by Product
• 2.3 Key Market Highlights by Technology
• 2.4 Key Market Highlights by Application
• 2.5 Key Market Highlights by End User
• 2.6 Key Market Highlights by Process
• 2.7 Key Market Highlights by Services
• 2.8 Key Market Highlights by Mode
• 2.9 Key Market Highlights by Stage

3 Market Dynamics

• 3.1 Macroeconomic Analysis
• 3.2 Market Trends
• 3.3 Market Drivers
• 3.4 Market Opportunities
• 3.5 Market Restraints
• 3.6 CAGR Growth Analysis
• 3.7 Impact Analysis
• 3.8 Emerging Markets
• 3.9 Technology Roadmap
• 3.10 Strategic Frameworks
  • 3.10.1 PORTER's 5 Forces Model
  • 3.10.2 ANSOFF Matrix
  • 3.10.3 4P's Model
  • 3.10.4 PESTEL Analysis

4 Segment Analysis

• 4.1 Market Size & Forecast by Type (2020-2035)
  • 4.1.1 Dengue
  • 4.1.2 Zika Virus
  • 4.1.3 Chikungunya
  • 4.1.4 Yellow Fever
  • 4.1.5 West Nile Virus
  • 4.1.6 Japanese Encephalitis
  • 4.1.7 Others
• 4.2 Market Size & Forecast by Product (2020-2035)
  • 4.2.1 Kits and Reagents
  • 4.2.2 Instruments
  • 4.2.3 Software
  • 4.2.4 Consumables
  • 4.2.5 Others
• 4.3 Market Size & Forecast by Technology (2020-2035)
  • 4.3.1 PCR-based
  • 4.3.2 ELISA
  • 4.3.3 Rapid Tests
  • 4.3.4 Immunoassays
  • 4.3.5 Others
• 4.4 Market Size & Forecast by Application (2020-2035)
  • 4.4.1 Clinical Testing
  • 4.4.2 Veterinary Testing
  • 4.4.3 Research
  • 4.4.4 Public Health Surveillance
  • 4.4.5 Others
• 4.5 Market Size & Forecast by End User (2020-2035)
  • 4.5.1 Hospitals
  • 4.5.2 Diagnostic Laboratories
  • 4.5.3 Research Institutes
  • 4.5.4 Public Health Organizations
  • 4.5.5 Others
• 4.6 Market Size & Forecast by Process (2020-2035)
  • 4.6.1 Sample Collection
  • 4.6.2 Sample Preparation
  • 4.6.3 Detection
  • 4.6.4 Analysis
  • 4.6.5 Others
• 4.7 Market Size & Forecast by Services (2020-2035)
  • 4.7.1 Diagnostic Services
  • 4.7.2 Consulting Services
  • 4.7.3 Training and Education
  • 4.7.4 Others
• 4.8 Market Size & Forecast by Mode (2020-2035)
  • 4.8.1 Point-of-Care Testing
  • 4.8.2 Laboratory Testing
  • 4.8.3 Others
• 4.9 Market Size & Forecast by Stage (2020-2035)
  • 4.9.1 Acute Phase Testing
  • 4.9.2 Convalescent Phase Testing
  • 4.9.3 Others

5 Regional Analysis

• 5.1 Global Market Overview
• 5.2 North America Market Size (2020-2035)
  • 5.2.1 United States
    • 5.2.1.1 Type
    • 5.2.1.2 Product
    • 5.2.1.3 Technology
    • 5.2.1.4 Application
    • 5.2.1.5 End User
    • 5.2.1.6 Process
    • 5.2.1.7 Services
    • 5.2.1.8 Mode
    • 5.2.1.9 Stage
  • 5.2.2 Canada
    • 5.2.2.1 Type
    • 5.2.2.2 Product
    • 5.2.2.3 Technology
    • 5.2.2.4 Application
    • 5.2.2.5 End User
    • 5.2.2.6 Process
    • 5.2.2.7 Services
    • 5.2.2.8 Mode
    • 5.2.2.9 Stage
  • 5.2.3 Mexico
    • 5.2.3.1 Type
    • 5.2.3.2 Product
    • 5.2.3.3 Technology
    • 5.2.3.4 Application
    • 5.2.3.5 End User
    • 5.2.3.6 Process
    • 5.2.3.7 Services
    • 5.2.3.8 Mode
    • 5.2.3.9 Stage
• 5.3 Latin America Market Size (2020-2035)
  • 5.3.1 Brazil
    • 5.3.1.1 Type
    • 5.3.1.2 Product
    • 5.3.1.3 Technology
    • 5.3.1.4 Application
    • 5.3.1.5 End User
    • 5.3.1.6 Process
    • 5.3.1.7 Services
    • 5.3.1.8 Mode
    • 5.3.1.9 Stage
  • 5.3.2 Argentina
    • 5.3.2.1 Type
    • 5.3.2.2 Product
    • 5.3.2.3 Technology
    • 5.3.2.4 Application
    • 5.3.2.5 End User
    • 5.3.2.6 Process
    • 5.3.2.7 Services
    • 5.3.2.8 Mode
    • 5.3.2.9 Stage
  • 5.3.3 Rest of Latin America
    • 5.3.3.1 Type
    • 5.3.3.2 Product
    • 5.3.3.3 Technology
    • 5.3.3.4 Application
    • 5.3.3.5 End User
    • 5.3.3.6 Process
    • 5.3.3.7 Services
    • 5.3.3.8 Mode
    • 5.3.3.9 Stage
• 5.4 Asia-Pacific Market Size (2020-2035)
  • 5.4.1 China
    • 5.4.1.1 Type
    • 5.4.1.2 Product
    • 5.4.1.3 Technology
    • 5.4.1.4 Application
    • 5.4.1.5 End User
    • 5.4.1.6 Process
    • 5.4.1.7 Services
    • 5.4.1.8 Mode
    • 5.4.1.9 Stage
  • 5.4.2 India
    • 5.4.2.1 Type
    • 5.4.2.2 Product
    • 5.4.2.3 Technology
    • 5.4.2.4 Application
    • 5.4.2.5 End User
    • 5.4.2.6 Process
    • 5.4.2.7 Services
    • 5.4.2.8 Mode
    • 5.4.2.9 Stage
  • 5.4.3 South Korea
    • 5.4.3.1 Type
    • 5.4.3.2 Product
    • 5.4.3.3 Technology
    • 5.4.3.4 Application
    • 5.4.3.5 End User
    • 5.4.3.6 Process
    • 5.4.3.7 Services
    • 5.4.3.8 Mode
    • 5.4.3.9 Stage
  • 5.4.4 Japan
    • 5.4.4.1 Type
    • 5.4.4.2 Product
    • 5.4.4.3 Technology
    • 5.4.4.4 Application
    • 5.4.4.5 End User
    • 5.4.4.6 Process
    • 5.4.4.7 Services
    • 5.4.4.8 Mode
    • 5.4.4.9 Stage
  • 5.4.5 Australia
    • 5.4.5.1 Type
    • 5.4.5.2 Product
    • 5.4.5.3 Technology
    • 5.4.5.4 Application
    • 5.4.5.5 End User
    • 5.4.5.6 Process
    • 5.4.5.7 Services
    • 5.4.5.8 Mode
    • 5.4.5.9 Stage
  • 5.4.6 Taiwan
    • 5.4.6.1 Type
    • 5.4.6.2 Product
    • 5.4.6.3 Technology
    • 5.4.6.4 Application
    • 5.4.6.5 End User
    • 5.4.6.6 Process
    • 5.4.6.7 Services
    • 5.4.6.8 Mode
    • 5.4.6.9 Stage
  • 5.4.7 Rest of APAC
    • 5.4.7.1 Type
    • 5.4.7.2 Product
    • 5.4.7.3 Technology
    • 5.4.7.4 Application
    • 5.4.7.5 End User
    • 5.4.7.6 Process
    • 5.4.7.7 Services
    • 5.4.7.8 Mode
    • 5.4.7.9 Stage
• 5.5 Europe Market Size (2020-2035)
  • 5.5.1 Germany
    • 5.5.1.1 Type
    • 5.5.1.2 Product
    • 5.5.1.3 Technology
    • 5.5.1.4 Application
    • 5.5.1.5 End User
    • 5.5.1.6 Process
    • 5.5.1.7 Services
    • 5.5.1.8 Mode
    • 5.5.1.9 Stage
  • 5.5.2 France
    • 5.5.2.1 Type
    • 5.5.2.2 Product
    • 5.5.2.3 Technology
    • 5.5.2.4 Application
    • 5.5.2.5 End User
    • 5.5.2.6 Process
    • 5.5.2.7 Services
    • 5.5.2.8 Mode
    • 5.5.2.9 Stage
  • 5.5.3 United Kingdom
    • 5.5.3.1 Type
    • 5.5.3.2 Product
    • 5.5.3.3 Technology
    • 5.5.3.4 Application
    • 5.5.3.5 End User
    • 5.5.3.6 Process
    • 5.5.3.7 Services
    • 5.5.3.8 Mode
    • 5.5.3.9 Stage
  • 5.5.4 Spain
    • 5.5.4.1 Type
    • 5.5.4.2 Product
    • 5.5.4.3 Technology
    • 5.5.4.4 Application
    • 5.5.4.5 End User
    • 5.5.4.6 Process
    • 5.5.4.7 Services
    • 5.5.4.8 Mode
    • 5.5.4.9 Stage
  • 5.5.5 Italy
    • 5.5.5.1 Type
    • 5.5.5.2 Product
    • 5.5.5.3 Technology
    • 5.5.5.4 Application
    • 5.5.5.5 End User
    • 5.5.5.6 Process
    • 5.5.5.7 Services
    • 5.5.5.8 Mode
    • 5.5.5.9 Stage
  • 5.5.6 Rest of Europe
    • 5.5.6.1 Type
    • 5.5.6.2 Product
    • 5.5.6.3 Technology
    • 5.5.6.4 Application
    • 5.5.6.5 End User
    • 5.5.6.6 Process
    • 5.5.6.7 Services
    • 5.5.6.8 Mode
    • 5.5.6.9 Stage
• 5.6 Middle East & Africa Market Size (2020-2035)
  • 5.6.1 Saudi Arabia
    • 5.6.1.1 Type
    • 5.6.1.2 Product
    • 5.6.1.3 Technology
    • 5.6.1.4 Application
    • 5.6.1.5 End User
    • 5.6.1.6 Process
    • 5.6.1.7 Services
    • 5.6.1.8 Mode
    • 5.6.1.9 Stage
  • 5.6.2 United Arab Emirates
    • 5.6.2.1 Type
    • 5.6.2.2 Product
    • 5.6.2.3 Technology
    • 5.6.2.4 Application
    • 5.6.2.5 End User
    • 5.6.2.6 Process
    • 5.6.2.7 Services
    • 5.6.2.8 Mode
    • 5.6.2.9 Stage
  • 5.6.3 South Africa
    • 5.6.3.1 Type
    • 5.6.3.2 Product
    • 5.6.3.3 Technology
    • 5.6.3.4 Application
    • 5.6.3.5 End User
    • 5.6.3.6 Process
    • 5.6.3.7 Services
    • 5.6.3.8 Mode
    • 5.6.3.9 Stage
  • 5.6.4 Sub-Saharan Africa
    • 5.6.4.1 Type
    • 5.6.4.2 Product
    • 5.6.4.3 Technology
    • 5.6.4.4 Application
    • 5.6.4.5 End User
    • 5.6.4.6 Process
    • 5.6.4.7 Services
    • 5.6.4.8 Mode
    • 5.6.4.9 Stage
  • 5.6.5 Rest of MEA
    • 5.6.5.1 Type
    • 5.6.5.2 Product
    • 5.6.5.3 Technology
    • 5.6.5.4 Application
    • 5.6.5.5 End User
    • 5.6.5.6 Process
    • 5.6.5.7 Services
    • 5.6.5.8 Mode
    • 5.6.5.9 Stage

6 Market Strategy

• 6.1 Demand-Supply Gap Analysis
• 6.2 Trade & Logistics Constraints
• 6.3 Price-Cost-Margin Trends
• 6.4 Market Penetration
• 6.5 Consumer Analysis
• 6.6 Regulatory Snapshot

7 Competitive Intelligence

• 7.1 Market Positioning
• 7.2 Market Share
• 7.3 Competition Benchmarking
• 7.4 Top Company Strategies

8 Company Profiles

• 8.1 Roche Diagnostics
  • 8.1.1 Overview
  • 8.1.2 Product Summary
  • 8.1.3 Financial Performance
  • 8.1.4 SWOT Analysis
• 8.2 Thermo Fisher Scientific
  • 8.2.1 Overview
  • 8.2.2 Product Summary
  • 8.2.3 Financial Performance
  • 8.2.4 SWOT Analysis
• 8.3 Abbott Laboratories
  • 8.3.1 Overview
  • 8.3.2 Product Summary
  • 8.3.3 Financial Performance
  • 8.3.4 SWOT Analysis
• 8.4 Bio-Rad Laboratories
  • 8.4.1 Overview
  • 8.4.2 Product Summary
  • 8.4.3 Financial Performance
  • 8.4.4 SWOT Analysis
• 8.5 Qiagen
  • 8.5.1 Overview
  • 8.5.2 Product Summary
  • 8.5.3 Financial Performance
  • 8.5.4 SWOT Analysis
• 8.6 Siemens Healthineers
  • 8.6.1 Overview
  • 8.6.2 Product Summary
  • 8.6.3 Financial Performance
  • 8.6.4 SWOT Analysis
• 8.7 PerkinElmer
  • 8.7.1 Overview
  • 8.7.2 Product Summary
  • 8.7.3 Financial Performance
  • 8.7.4 SWOT Analysis
• 8.8 Hologic
  • 8.8.1 Overview
  • 8.8.2 Product Summary
  • 8.8.3 Financial Performance
  • 8.8.4 SWOT Analysis
• 8.9 bioMerieux
  • 8.9.1 Overview
  • 8.9.2 Product Summary
  • 8.9.3 Financial Performance
  • 8.9.4 SWOT Analysis
• 8.10 Danaher Corporation
  • 8.10.1 Overview
  • 8.10.2 Product Summary
  • 8.10.3 Financial Performance
  • 8.10.4 SWOT Analysis
• 8.11 Becton Dickinson and Company
  • 8.11.1 Overview
  • 8.11.2 Product Summary
  • 8.11.3 Financial Performance
  • 8.11.4 SWOT Analysis
• 8.12 Agilent Technologies
  • 8.12.1 Overview
  • 8.12.2 Product Summary
  • 8.12.3 Financial Performance
  • 8.12.4 SWOT Analysis
• 8.13 Merck KGaA
  • 8.13.1 Overview
  • 8.13.2 Product Summary
  • 8.13.3 Financial Performance
  • 8.13.4 SWOT Analysis
• 8.14 Luminex Corporation
  • 8.14.1 Overview
  • 8.14.2 Product Summary
  • 8.14.3 Financial Performance
  • 8.14.4 SWOT Analysis
• 8.15 Cepheid
  • 8.15.1 Overview
  • 8.15.2 Product Summary
  • 8.15.3 Financial Performance
  • 8.15.4 SWOT Analysis
• 8.16 Ortho Clinical Diagnostics
  • 8.16.1 Overview
  • 8.16.2 Product Summary
  • 8.16.3 Financial Performance
  • 8.16.4 SWOT Analysis
• 8.17 DiaSorin
  • 8.17.1 Overview
  • 8.17.2 Product Summary
  • 8.17.3 Financial Performance
  • 8.17.4 SWOT Analysis
• 8.18 Sysmex Corporation
  • 8.18.1 Overview
  • 8.18.2 Product Summary
  • 8.18.3 Financial Performance
  • 8.18.4 SWOT Analysis
• 8.19 Grifols
  • 8.19.1 Overview
  • 8.19.2 Product Summary
  • 8.19.3 Financial Performance
  • 8.19.4 SWOT Analysis
• 8.20 Quidel Corporation
  • 8.20.1 Overview
  • 8.20.2 Product Summary
  • 8.20.3 Financial Performance
  • 8.20.4 SWOT Analysis

9 About Us

• 9.1 About Us
• 9.2 Research Methodology
• 9.3 Research Workflow
• 9.4 Consulting Services
• 9.5 Our Clients
• 9.6 Client Testimonials
• 9.7 Contact Us